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Background: Severe early-onset intrauterine growth restriction (IUGR) carries significant risk of mortality and morbidity. There are currently no effective therapies. Sildenafil, a nitricoxide mediated vasodilator, has been proposed as a potential treatment for IUGR and other antenatal conditions. We prospectively evaluated the effect of antenatal sildenafil exposure on neonatal cardiac function in a sub-group of infants born to women in the STRIDER NZAus trial. The recent cessation of a similar Dutch trial due to concerns of increased neonatal pulmonary hypertension increases the importance of this data.
Methods: STRIDER-NZAus was a randomised placebocontrolled trial of sildenafil in severe early-onset IUGR in 13 Maternal-Foetal Medicine units across New Zealand and Australia. In this sub-study, cord blood was collected for measurement of the cardiac biomarker NTproBNP and infants underwent echocardiography on days 1 and 3.
Results: 27 infants (14 sildenafil, 13 placebo) were assessed, median (IQR) gestation 35.4 (26.0, 38. 3) weeks and birthweight z-score -2.1 (-4.7, -0.8) . NTproBNP and indices of cardiac function were within normal range for age. The only significant difference between groups was a lower rate of patent ductus arteriosus on day 1 in infants exposed to sildenafil (42% vs 91%, P=0.01). Measures of cardiac function (RVCO, SVC flow, TAPSE, MPI) and pulmonary artery pressure (TR, IVS) were similar between groups. No infant in this sub-study had pulmonary hypertension.
Conclusion: We found no association of sildenafil with neonatal cardiac dysfunction or pulmonary hypertension. Neonatal cardiac evaluation is recommended for infants in any further trials of sildenafil in pregnancy. Background: Prompt treatment is recommended for hypoglycaemia, yet there is a paucity of evidence describing normal glucose profiles after birth.
GLUCOSE PROFILES IN HEALTHY TERM BABIES IN THE FIRST FIVE DAYS: THE GLUCOSE IN WELL BABIES (GLOW) STUDY
Methods: Term, appropriately grown, healthy singletons had continuous glucose monitoring and heel-prick blood samples for 5 days (4 in the first 24 h then twice daily, glucose oxidase method).
Results: 67 babies completed the study. Glucose concentrations were stable over the first 48h and then increased to a new plateau after 72h (Table) . Hypoglycaemia (< 2.6mM) was common particularly in the first 48 h. Babies < 40 weeks' gestation had more hypoglycaemia (P= 0.001). Methods: Term, appropriately grown, healthy singletons had continuous interstitial and blood glucose concentrations measured over the first 5 days (4 capillary heel-prick blood samples in the first 24 h then twice daily, glucose oxidase method). We calculated the proportion who fell below hypoglycaemia treatment thresholds recommended by different international guidelines.
Results: 67 babies completed the study. Between 2 and 86% of babies had blood glucose concentrations below the recommended treatment thresholds (Table) . Number (%) of babies with glucose concentrations below recommended thresholds for treatment
